Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.

Wilcox J, Potter D, Moore M, Ferrande L, Kelly E

Fertility and sterility1 Jul 2005Cited by 33 (Europe PMC)

PMID16009165DOI10.1016/j.fertnstert.2005.03.016PepBankPUB-16009165

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In infertile ART patients, no premature LH surge occurred with either cetrorelix or ganirelix.
In plain wordsIn infertile ART patients, neither cetrorelix nor ganirelix groups had premature LH surges.
Peptide
Cetrorelix
Outcome
Not applicablePremature LH surge
Study
n = 185
Comparator
Ganirelix 0.25 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg, with daily 0.25 mg if hCG criteria were unmet after 4 days · SCAs given in this study (human).
Source sentences
Summary
No patient in either treatment group had a premature LH surge.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916501
02HumanRandomized controlled trialEfficacy outcome
In infertile ART patients, no premature LH surge occurred with either ganirelix or cetrorelix.
In plain wordsIn infertile ART patients, neither ganirelix nor cetrorelix groups had premature LH surges.
Peptide
Ganirelix
Outcome
Not applicablePremature LH surge
Study
n = 185
Comparator
Cetrorelix 3 mg with conditional daily 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · SCAs given in this study (human).
Source sentences
Summary
No patient in either treatment group had a premature LH surge.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916502
03HumanRandomized controlled trialEfficacy outcome
In infertile ART patients, IVF/ICSI and embryo transfer outcomes, including pregnancy, did not differ significantly between cetrorelix and ganirelix.
In plain wordsIn infertile ART patients, IVF and embryo transfer outcomes, including pregnancy, did not differ significantly between cetrorelix and ganirelix.
Peptide
Cetrorelix
Outcome
No significant changeIVF/ICSI and embryo transfer outcomes including pregnancy
Study
n = 185
Comparator
Ganirelix 0.25 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg, with daily 0.25 mg if hCG criteria were unmet after 4 days · SCAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences between treatments for any IVF/intracytoplasmic sperm injection (ICSI) or ET outcomes, including pregnancy rate (PR).
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916503
04HumanRandomized controlled trialEfficacy outcome
In infertile ART patients, IVF/ICSI and embryo transfer outcomes, including pregnancy, did not differ significantly between ganirelix and cetrorelix.
In plain wordsIn infertile ART patients, IVF and embryo transfer outcomes, including pregnancy, did not differ significantly between ganirelix and cetrorelix.
Peptide
Ganirelix
Outcome
No significant changeIVF/ICSI and embryo transfer outcomes including pregnancy
Study
n = 185
Comparator
Cetrorelix 3 mg with conditional daily 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · SCAs given in this study (human).
Source sentences
Summary
There were no statistically significant differences between treatments for any IVF/intracytoplasmic sperm injection (ICSI) or ET outcomes, including pregnancy rate (PR).
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916504
05HumanRandomized controlled trialEfficacy outcome
In infertile ART patients, cetrorelix required significantly fewer injections than ganirelix.
In plain wordsIn infertile ART patients, cetrorelix required fewer injections than ganirelix.
Peptide
Cetrorelix
Outcome
DecreaseNumber of injections
Study
n = 185
Comparator
Ganirelix 0.25 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3 mg, with daily 0.25 mg if hCG criteria were unmet after 4 days · SCAs given in this study (human).
Source sentences
Summary
However, cetrorelix required significantly fewer injections than ganirelix.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916505
06HumanRandomized controlled trialEfficacy outcome
In infertile ART patients, ganirelix required significantly more injections than cetrorelix.
In plain wordsIn infertile ART patients, ganirelix required more injections than cetrorelix.
Peptide
Ganirelix
Outcome
IncreaseNumber of injections
Study
n = 185
Comparator
Cetrorelix 3 mg with conditional daily 0.25 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · SCAs given in this study (human).
Source sentences
Summary
However, cetrorelix required significantly fewer injections than ganirelix.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916506
07HumanRandomized controlled trialSafety outcome
In infertile ART patients, cetrorelix and ganirelix had similar safety profiles.
In plain wordsIn infertile ART patients, cetrorelix and ganirelix had similar safety profiles.
Peptide
Cetrorelix
Outcome
Direction not reportedSafety profile
Study
n = 185
Comparator
Ganirelix 0.25 mg daily
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
3 mg, with daily 0.25 mg if hCG criteria were unmet after 4 days · SCAs given in this study (human).
Source sentences
Summary
Similar safety profiles were observed.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916507
08HumanRandomized controlled trialSafety outcome
In infertile ART patients, ganirelix and cetrorelix had similar safety profiles.
In plain wordsIn infertile ART patients, ganirelix and cetrorelix had similar safety profiles.
Peptide
Ganirelix
Outcome
Direction not reportedSafety profile
Study
n = 185
Comparator
Cetrorelix 3 mg with conditional daily 0.25 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · SCAs given in this study (human).
Source sentences
Summary
Similar safety profiles were observed.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, open-label, randomized, comparative study.
Summary · context
One hundred eighty-five infertile patients undergoing ART.
Summary · context
Single injection of cetrorelix (3 mg SC) or daily dose of ganirelix (0.25 mg SC) was administered when the lead follicle was > or =14 mm.
Summary · context
Daily cetrorelix (0.25 mg) was administered if the criteria for hCG administration were not met 4 days after receiving 3 mg of cetrorelix.
Report a problemFND-1600916508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00298025

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

EMD Seronon = 185Sept 2003 to May 2004

Infertile Women Undergoing Assisted Reproductive Technology (ART)

Trial page ClinicalTrials.govUpdated 26 Mar 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC